# Study of ENMD-2076 in Patients With Multiple Myeloma

> **NCT00806065** · PHASE1 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ENMD-2076

## Key facts

- **NCT ID:** NCT00806065
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2011-11
- **Final completion:** 2012-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806065, "Study of ENMD-2076 in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00806065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*